Evan A. Thackaberry

830 total citations
29 papers, 574 citations indexed

About

Evan A. Thackaberry is a scholar working on Ophthalmology, Molecular Biology and Immunology. According to data from OpenAlex, Evan A. Thackaberry has authored 29 papers receiving a total of 574 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Ophthalmology, 8 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Evan A. Thackaberry's work include Retinal Diseases and Treatments (7 papers), Computational Drug Discovery Methods (4 papers) and Inflammation biomarkers and pathways (4 papers). Evan A. Thackaberry is often cited by papers focused on Retinal Diseases and Treatments (7 papers), Computational Drug Discovery Methods (4 papers) and Inflammation biomarkers and pathways (4 papers). Evan A. Thackaberry collaborates with scholars based in United States, Switzerland and Canada. Evan A. Thackaberry's co-authors include Mary Walker, Susan M. Smith, Vladimir Bantseev, Florence Lorget, Cindy Farman, Jiang Zhou, K. S. Ramos, Charles D. Johnson, Irena Ivnitski‐Steele and Barry Mcintyre and has published in prestigious journals such as Neurology, Investigative Ophthalmology & Visual Science and Drug Discovery Today.

In The Last Decade

Evan A. Thackaberry

28 papers receiving 553 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Evan A. Thackaberry United States 14 167 139 114 83 71 29 574
Robert W. Tuman United States 14 300 1.8× 73 0.5× 23 0.2× 29 0.3× 23 0.3× 27 588
Natalie Lassen United States 11 441 2.6× 23 0.2× 36 0.3× 87 1.0× 126 1.8× 18 775
Jianjun Chen China 14 303 1.8× 37 0.3× 62 0.5× 17 0.2× 26 0.4× 42 641
Charles B. Spainhour United States 13 155 0.9× 36 0.3× 8 0.1× 18 0.2× 34 0.5× 23 397
Masato Mutoh Japan 15 419 2.5× 34 0.2× 18 0.2× 20 0.2× 74 1.0× 21 981
Jacquelyn J. Bower United States 13 428 2.6× 87 0.6× 20 0.2× 35 0.4× 74 1.0× 27 678
José Francisco Figueiredo Brazil 10 309 1.9× 15 0.1× 11 0.1× 84 1.0× 17 0.2× 17 895
Michael J. Graziano United States 18 400 2.4× 33 0.2× 5 0.0× 24 0.3× 195 2.7× 56 801
Ali M. Saboori United States 16 210 1.3× 47 0.3× 5 0.0× 39 0.5× 27 0.4× 23 678
Siobhan E. Moriarty-Craige United States 7 327 2.0× 26 0.2× 62 0.5× 35 0.4× 19 0.3× 7 618

Countries citing papers authored by Evan A. Thackaberry

Since Specialization
Citations

This map shows the geographic impact of Evan A. Thackaberry's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Evan A. Thackaberry with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Evan A. Thackaberry more than expected).

Fields of papers citing papers by Evan A. Thackaberry

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Evan A. Thackaberry. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Evan A. Thackaberry. The network helps show where Evan A. Thackaberry may publish in the future.

Co-authorship network of co-authors of Evan A. Thackaberry

This figure shows the co-authorship network connecting the top 25 collaborators of Evan A. Thackaberry. A scholar is included among the top collaborators of Evan A. Thackaberry based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Evan A. Thackaberry. Evan A. Thackaberry is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gergits, Frederick W., Abigail J. Renoux, Borislav Dejanovic, et al.. (2025). Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonism. Journal of Neuroinflammation. 22(1). 26–26. 4 indexed citations
2.
Luetjens, C. Marc, Antje Fuchs, Peter J. Hall, et al.. (2025). Subcutaneous zilucoplan: Evaluation of reproductive toxicology. Reproductive Toxicology. 134. 108877–108877. 1 indexed citations
3.
Meier, Andreas, Spyros Papapetropoulos, Ryan O'Mara, et al.. (2025). Phase 1, First‐In‐Human, Single‐/Multiple‐Ascending Dose Study of Iluzanebart in Healthy Volunteers. Annals of Clinical and Translational Neurology. 12(5). 1065–1076. 1 indexed citations
4.
Mirescu, Christian, Borislav Dejanovic, Frederick W. Gergits, et al.. (2024). Pharmacological and functional characterization of the first small molecule TREM2 agonist, VG‐3927, for the treatment of Alzheimer’s disease. Alzheimer s & Dementia. 20(S6). 4 indexed citations
5.
Chan, Darren, A. Thomas Read, C. Ross Ethier, et al.. (2022). Application of an organotypic ocular perfusion model to assess intravitreal drug distribution in human and animal eyes. Journal of The Royal Society Interface. 19(186). 20210734–20210734. 3 indexed citations
6.
DeMarco, Steven J., et al.. (2020). Development of peptide therapeutics: A nonclinical safety assessment perspective. Regulatory Toxicology and Pharmacology. 117. 104766–104766. 15 indexed citations
7.
Bantseev, Vladimir, P. Elliott Miller, T. Michael Nork, et al.. (2019). Determination of a No Observable Effect Level for Endotoxin Following a Single Intravitreal Administration to Cynomolgus Monkeys. Journal of Ocular Pharmacology and Therapeutics. 35(4). 245–253. 9 indexed citations
8.
Zafra, Christina L. Zuch de, Vito G. Sasseville, Steven S. Matsumoto, et al.. (2017). Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics. Regulatory Toxicology and Pharmacology. 86. 221–230. 25 indexed citations
9.
Bantseev, Vladimir, et al.. (2017). Nonclinical Safety Assessment of Anti-Factor D: Key Strategies and Challenges for the Nonclinical Development of Intravitreal Biologics. Journal of Ocular Pharmacology and Therapeutics. 34(1-2). 204–213. 10 indexed citations
10.
Lorget, Florence, et al.. (2015). Characterization of the pH and Temperature in the Rabbit Vitreous: Key Parameters for the Development of Long Acting Delivery of Drugs to the Posterior Segment of the Eye. Investigative Ophthalmology & Visual Science. 56(7). 146–146. 1 indexed citations
11.
Zafra, Christina L. Zuch de, Cindy Farman, Eric Wakshull, et al.. (2015). Repeat-dose intravitreal administration of a humanized monoclonal antibody is poorly tolerated in rabbits. Investigative Ophthalmology & Visual Science. 56(7). 3640–3640. 1 indexed citations
12.
13.
Thackaberry, Evan A.. (2013). Vehicle selection for nonclinical oral safety studies. Expert Opinion on Drug Metabolism & Toxicology. 9(12). 1635–1646. 10 indexed citations
14.
Thackaberry, Evan A., Xiaojing Wang, Michelle Schweiger, et al.. (2013). Solvent-based formulations for intravenous mouse pharmacokinetic studies: tolerability and recommended solvent dose limits. Xenobiotica. 44(3). 235–241. 31 indexed citations
15.
Thackaberry, Evan A.. (2012). Non-clinical toxicological considerations for pharmaceutical salt selection. Expert Opinion on Drug Metabolism & Toxicology. 8(11). 1419–1433. 27 indexed citations
16.
17.
Thackaberry, Evan A., Jiang Zhou, Charles D. Johnson, K. S. Ramos, & Mary Walker. (2005). Toxicogenomic Profile of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin in the Murine Fetal Heart: Modulation of Cell Cycle and Extracellular Matrix Genes. Toxicological Sciences. 88(1). 231–241. 58 indexed citations
18.
19.
20.
Thackaberry, Evan A., et al.. (2002). Aryl Hydrocarbon Receptor Null Mice Develop Cardiac Hypertrophy and Increased Hypoxia-Inducible Factor-1α in the Absence of Cardiac Hypoxia. Cardiovascular Toxicology. 2(4). 263–274. 70 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Robert W. Tuman Breakdown of academic impact, for papers by Natalie Lassen Breakdown of academic impact, for papers by Jianjun Chen Breakdown of academic impact, for papers by Charles B. Spainhour Breakdown of academic impact, for papers by Masato Mutoh Breakdown of academic impact, for papers by Jacquelyn J. Bower Breakdown of academic impact, for papers by José Francisco Figueiredo Breakdown of academic impact, for papers by Michael J. Graziano Breakdown of academic impact, for papers by Ali M. Saboori Breakdown of academic impact, for papers by Siobhan E. Moriarty-Craige
Rankless by CCL
2026